Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
$RIGL
Biotechnology: Pharmaceutical Preparations
Health Care
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2023 | $2.00 | Neutral | Piper Sandler |
| 6/9/2022 | Buy → Neutral | Citigroup | |
| 6/8/2022 | $7.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 6/8/2022 | $6.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 3/23/2022 | $4.00 | Neutral | B. Riley Securities |
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00
Citigroup downgraded Rigel Pharma from Buy to Neutral
Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarterInitial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual MeetingConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rige
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's
Second quarter total revenue of $36.8 million, which includes TAVALISSE® net product sales of $26.4 million, REZLIDHIA® net product sales of $5.2 million and GAVRETO® net product sales of $1.9 millionSuccessfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June 27, 2024Conference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Aug. 6, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported fin
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST). To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotech
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarterInitial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual MeetingConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 7, 2024 /PRNewswire/ -- Rige
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif., Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually. Rigel's presentations will incl
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience to Rigel, including expertise in negotiating licensing, joint-venture, and M&A transactions to drive strategic growth. "Kamil is a savvy businessperson, has a sharp transactional mind, and is a serial entrepreneur who brings immense experience to our board," said Raul Rodriguez, president and CEO of Rigel. "Her experience as an international transaction attorney, litigator, biotech founder, and pharmaceutical executi
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol (RIGL) when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.The Reverse Stock Split was approved by the company's stockholders at its Annual Meeting of Stockholders held on May 24, 2024 to be effected by the company's Board of Directors (the "Board") within approved param
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15 price target.